Nivolumab,Ipilimumab
BMS
['#gi', 'nivo', 'gicsm']
neoadjuvant nivo-ipi produced an unprecedented major pathologic response rate in dmmr colon cancer, reported at #esmo22. #gicsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.